Outcomes of Hyperbaric Oxygen Therapy at 2.0 Versus 2.5 ATA for Hemorrhagic Radiation Cystitis | Canada Hyperbarics
Study Neurourol Urodyn 2026

Outcomes of Hyperbaric Oxygen Therapy at 2.0 Versus 2.5 ATA for Hemorrhagic Radiation Cystitis

Soriano V, Laspro M, Lee W, Parker S, Taneja S, Brucker B, et al. — Neurourol Urodyn, 2026

Tier 2 — Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers compared two HBOT pressures -- 2.0 ATA versus 2.5 ATA -- for treating hemorrhagic radiation cystitis in a cohort of 93 patients.

What They Found

Both pressures produced significant improvements in hematuria and cystitis symptoms. The 2.5 ATA group showed slightly greater improvement in objective bleeding scores, but both protocols were considered clinically effective with comparable safety profiles.

What This Means for Canadian Patients

Hemorrhagic radiation cystitis is an OHIP-covered indication for HBOT in Ontario. This comparative study helps inform which pressure protocol may be preferred in clinical practice at Canadian hyperbaric centres.

Canadian Relevance

Covers an OHIP-covered indication: delayed radiation injury (radiation cystitis). Ontario patients with hemorrhagic radiation cystitis following pelvic cancer treatment may be eligible for publicly funded HBOT.

Study Limitations

Retrospective design and lack of randomization limit conclusions about which pressure is definitively superior.

Was this summary helpful?

Study Details

Study Type Study
Category Radiation Injury
Source Pubmed
PubMed ID 41603214
Year Published 2026
Journal Neurourol Urodyn
MeSH Terms Humans; Hyperbaric Oxygenation; Cystitis; Retrospective Studies; Female; Radiation Injuries; Middle Aged; Hematuria; Male; Treatment Outcome; Aged; Hemorrhage; Time Factors; Adult; Radiotherapy; Recurrence

Cite This Study

Share

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.